Translate this page into:
Answer to Image Challenge: Cutaneous Lesions in a Case of Recurrent Carcinoma Buccal Mucosa on FDG/PET
*Corresponding author: Dr. Ameya D Puranik, Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Dr. E Borges Marg, Parel, Mumbai, Maharashtra, 400012, India. ameya2812@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Yadav MV, Rangarajan V, Puranik AD. Answer to Image Challenge: Cutaneous Lesions in a Case of Recurrent Carcinoma Buccal Mucosa on FDG/PET. Indian J Nucl Med. 2026;41:435. 2026;41:435. doi: 10.25259/IJNM_138_2026
Dermatologic side effects are relatively common among patients treated with epidermal growth factor receptor (EGFR) inhibitors, especially for metastatic pancreatic, lung and head and neck cancers. These skin disorders are generally mild or moderate in severity and can be managed by appropriate interventions or by reducing or interrupting the erlotinib dose. The classic rash occurs within the first 1–3 weeks of treatment.[1]
It affects sebaceous gland-rich areas like the face, scalp, and upper torso. While a papulopustular (acne-like) rash is most common, reactions can also present with lichenoid (scaling, purple-tinted, inflammatory plaques) or pustular (pus-filled, blister-like) features.[2]
References
- Erlotinib-associated rash in advanced non-small cell lung cancer: Relation to clinicopathological characteristics, treatment response, and survival. Oncol Res. 2018;26:59-69.
- [CrossRef] [PubMed] [Google Scholar]
- Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69:463-72.
- [CrossRef] [PubMed] [Google Scholar]